| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Polycomb protein SUZ12, Chromatin precipitated E2F target 9 protein, ChET 9 protein, Joined to JAZF1 protein, Suppressor of zeste 12 protein homolog, SUZ12, CHET9, JJAZ1, KIAA0160 |
| Entrez GeneID | 23512 |
| WB Predicted band size | 83.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This SUZ12 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 559-588 amino acids from the C-terminal region of human SUZ12. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于SUZ12抗体的参考文献及其摘要概述：
---
1. **"SUZ12 is essential for mouse development and histone H3 lysine 27 trimethylation"**
*Authors: Cao R, et al. (2004)*
摘要：该研究通过基因敲除实验证实SUZ12是PRC2复合体的核心组分，对其介导的H3K27me3修饰至关重要。文中使用SUZ12抗体进行免疫沉淀和染色质分析，揭示了SUZ12在胚胎发育中的必要功能。
2. **"Characterization of the polycomb repressive complex 2 in human tumors"**
*Authors: Pasini D, et al. (2008)*
摘要：研究通过多种SUZ12抗体(包括ChIP和Western blot)分析PRC2在癌症中的表达，发现SUZ12缺失导致H3K27me3水平下降，并促进肿瘤抑制基因异常激活，提示其作为抑癌因子的潜在作用。
3. **"Recurrent mutations in polycomb complex genes in human cancers"**
*Authors: Lee W, et al. (2013)*
摘要：利用SUZ12抗体进行免疫组化及基因测序，发现多种癌症中存在SUZ12功能缺失突变，导致PRC2复合体失活，进而影响表观遗传调控和肿瘤发生机制。
---
如需更具体的研究或近年文献，可补充说明方向(如抗体应用技术、疾病模型等)。
The SUZ12 antibody is a crucial tool for studying the Polycomb Repressive Complex 2 (PRC2), a key epigenetic regulator involved in gene silencing. SUZ12 (Suppressor of Zeste 12 homolog) is one of the core subunits of PRC2. along with EZH2. EED, and RbAp46/48. This complex catalyzes the trimethylation of histone H3 at lysine 27 (H3K27me3), a hallmark of transcriptionally repressive chromatin. SUZ12 is essential for PRC2 stability and enzymatic activity, as its absence disrupts complex assembly and H3K27me3 deposition.
Antibodies targeting SUZ12 are widely used to investigate PRC2's role in development, differentiation, and disease. They enable the detection of SUZ12 protein expression, localization, and interaction partners through techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP). These applications have revealed SUZ12's involvement in maintaining stem cell pluripotency, X-chromosome inactivation, and tumor suppression. Dysregulation of SUZ12. often observed in cancers and developmental disorders, underscores its biological significance.
Commercial SUZ12 antibodies are typically raised against specific epitopes (e.g., human SUZ12 N- or C-terminal regions) and validated for species cross-reactivity (human, mouse, rat). Researchers must verify antibody specificity using knockout controls or siRNA-mediated SUZ12 depletion, as off-target binding can occur. Optimizing experimental conditions (e.g., fixation methods for ChIP) is critical for reliable results. As PRC2-targeted therapies emerge, SUZ12 antibodies remain vital for dissecting epigenetic mechanisms in health and disease.
×
